2065438+March 30, 2007 On the 30th, the State Food and Drug Administration notified five batches of unqualified drugs on its website, claiming that five batches of drugs produced by four enterprises including Shanxi Guorun Pharmaceutical Co., Ltd. were unqualified. The food and drug administrations of relevant provinces (autonomous regions and municipalities) have asked enterprises to suspend sales and use, recall products and carry out rectification.
According to the report, five batches of drugs produced by four enterprises, including Shanxi Guorun Pharmaceutical Co., Ltd., failed the inspection by Heilongjiang Food and Drug Inspection and Research Institute.
The manufacturer, drug name and batch number of unqualified products are: 140500 1,150401,and Changchun Changhong Pharmaceutical Co., Ltd. has a batch number of 20160655. Benproperine phosphate tablets with batch number 150902 produced by Tonghua Great Wall Pharmaceutical Co., Ltd. and Benproperine phosphate capsules with batch number 160606 produced by Tianjin Jinhong Shengli Pharmaceutical Co., Ltd. The unqualified items include dissolution, content uniformity and content determination.
For the above-mentioned unqualified drugs, the food and drug administration of the relevant provinces (autonomous regions and municipalities) has taken control measures such as sealing up and detaining, requiring enterprises to suspend sales and use, recall products and carry out rectification.
China Food and Drug Administration requires the food and drug administration of the provinces (autonomous regions and municipalities) where the production enterprises are located to file an investigation on the illegal acts of the above-mentioned enterprises in producing and selling substandard drugs in accordance with Articles 73, 74 and 75 of the Drug Administration Law of People's Republic of China (PRC), and disclose the results of the treatment of enterprises or units related to the production and sale of substandard drugs within three months, and report the relevant information to the General Administration in a timely manner.
The US Food and Drug Administration announced that 35 batches of Eucommia ulmoides pieces were unqualified.
2065438+March 27th, 2007 China Food and Drug Administration recently issued an announcement, marking 35 batches of Eucommia ulmoides Oliv. The pieces produced by Beijing Tongrentang (Bozhou) Pieces Co., Ltd. and other enterprises are unqualified.
According to the report, the unqualified products involved Beijing Tongrentang (Bozhou) Pieces Co., Ltd., Hangzhou Huadong Traditional Chinese Medicine Pieces Co., Ltd., Anguo Qi 'an Pharmaceutical Co., Ltd., An Traditional Chinese Medicine Pieces Factory Co., Ltd. and many other enterprises. Unqualified items include content determination and characters.
For the above-mentioned unqualified Chinese herbal pieces, the relevant provincial food and drug administration has taken control measures such as sealing up and detaining, requiring enterprises to suspend sales and use, recall products and carry out rectification.
The US Food and Drug Administration requires the provincial food and drug administration where the manufacturer is located to investigate the illegal activities of producing and selling unqualified products in accordance with relevant regulations, and publicly handle the results within three months.
According to the circular, Xi 'an Chinese Herbal Pieces Factory Co., Ltd. and other label manufacturers denied that the unqualified products were produced by their own enterprises. Regarding the enterprise's objection to the authenticity of the product, the Food and Drug Administration pointed out that the enterprise can submit it to the local provincial food and drug administration, which will investigate and verify the production and sales of the enterprise and inform the provincial food and drug administration where the sampled unit is located. After receiving the notification, the provincial food and drug administration where the sampled unit is located shall immediately file an investigation and trace the source of the product. If it is indeed produced by a label manufacturer, the relevant provincial food and drug administration will severely punish the manufacturer.